Sonnet BioTherapeutics I... (SONN)
Sonnet BioTherapeutics Statistics
Share Statistics
Sonnet BioTherapeutics has 3.07M shares outstanding. The number of shares has increased by -2.02% in one year.
| Shares Outstanding | 3.07M |
| Shares Change (YoY) | -2.02% |
| Shares Change (QoQ) | 362.46% |
| Owned by Institutions (%) | 0.05% |
| Shares Floating | 3.03M |
| Failed to Deliver (FTD) Shares | 583 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 40.12K, so 1.33% of the outstanding shares have been sold short.
| Short Interest | 40.12K |
| Short % of Shares Out | 1.33% |
| Short % of Float | 1.35% |
| Short Ratio (days to cover) | 0.03 |
Valuation Ratios
The PE ratio is -0.59 and the forward PE ratio is -0.12. Sonnet BioTherapeutics's PEG ratio is 0.02.
| PE Ratio | -0.59 |
| Forward PE | -0.12 |
| PS Ratio | 235.35 |
| Forward PS | 1383.3 |
| PB Ratio | -9.02 |
| P/FCF Ratio | -0.51 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Sonnet BioTherapeutics Inc. has an Enterprise Value (EV) of 909.25K.
| EV / Earnings | -0.12 |
| EV / Sales | 48.82 |
| EV / EBITDA | -0.08 |
| EV / EBIT | -0.08 |
| EV / FCF | -0.11 |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of -0.27.
| Current Ratio | 0.66 |
| Quick Ratio | 0.66 |
| Debt / Equity | -0.27 |
| Total Debt / Capitalization | -36.88 |
| Cash Flow / Debt | -65.78 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 15.31% and return on capital (ROIC) is 3339.05%.
| Return on Equity (ROE) | 15.31% |
| Return on Assets (ROA) | -2.68% |
| Return on Capital (ROIC) | 3339.05% |
| Revenue Per Employee | 1.43K |
| Profits Per Employee | -572.09K |
| Employee Count | 13 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -89.36% in the last 52 weeks. The beta is 1.03, so Sonnet BioTherapeutics's price volatility has been higher than the market average.
| Beta | 1.03 |
| 52-Week Price Change | -89.36% |
| 50-Day Moving Average | 1.6 |
| 200-Day Moving Average | 5.57 |
| Relative Strength Index (RSI) | 45.4 |
| Average Volume (20 Days) | 1.06M |
Income Statement
In the last 12 months, Sonnet BioTherapeutics had revenue of 18.63K and earned -7.44M in profits. Earnings per share was -11.35.
| Revenue | 18.63K |
| Gross Profit | 18.63K |
| Operating Income | -11.85M |
| Net Income | -7.44M |
| EBITDA | -11.85M |
| EBIT | -11.85M |
| Earnings Per Share (EPS) | -11.35 |
Balance Sheet
The company has 149.46K in cash and 130.86K in debt, giving a net cash position of 18.59K.
| Cash & Cash Equivalents | 149.46K |
| Total Debt | 130.86K |
| Net Cash | 18.59K |
| Retained Earnings | -117.68M |
| Total Assets | 7.18M |
| Working Capital | 3.6M |
Cash Flow
In the last 12 months, operating cash flow was -8.61M and capital expenditures 0, giving a free cash flow of -8.61M.
| Operating Cash Flow | -8.61M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.61M |
| FCF Per Share | -13.14 |
Margins
Gross margin is 100%, with operating and profit margins of -63.62K% and -39.93K%.
| Gross Margin | 100% |
| Operating Margin | -63.62K% |
| Pretax Margin | -39.93K% |
| Profit Margin | -39.93K% |
| EBITDA Margin | -63.62K% |
| EBIT Margin | -63.62K% |
| FCF Margin | -46.21K% |
Dividends & Yields
SONN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -737.01% |
| FCF Yield | -182.32% |
Analyst Forecast
The average price target for SONN is $38, which is 2367.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 2367.5% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Sep 30, 2024. It was a backward split with a ratio of 1:8.
| Last Split Date | Sep 30, 2024 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -28.08 |
| Piotroski F-Score | 5 |